阿斯利康将向许可方支付合计12亿美元的总首付款，其中巨石生物收取的首付款金额为总首付款金额的 35%。阿斯利康将根据许可区域范围内的开发、上市和销售等情况，向许可方支付相应里程碑款项。阿 斯利康将向许可方累计支付最高35亿美元的开发里程碑款项、最高138亿美元的销售里程碑款项。其 中，巨石生物将有权根据《战略合作与授权协议》所授权管线的实际情况收取相应的开发里程碑款项和 销售里程碑款项。 本次交易有利于加快公司相关创新药管线在全球范围内的开发和商业化进程，对公司深化全球布局、加 速创新成果转化具有重要意义。本次交易将持续优化公司现金流结构，加速前期研发投入回收，为后续 创新药管线的持续研发提供稳定的资金支持，高度契合公司加速打造领先的创新生物医药平台的长期发 展战略，有利于促进公司的长远可持续发展，对公司的未来经营发展将产生较大的积极影响。 新诺威（300765）(300765.SZ)发布公告，公司的控股子公司石药集团巨石生物制药有限公司(以下简 称"巨石生物")及公司的关联方石药集团有限公司(以下简称"石药集团")、石药集团中奇制药技术(石家 庄)有限公司(以下简称"中奇制药")共同与阿斯利康于2026年1 ...

Core Viewpoint - The establishment of a joint venture between XinNuoWei and Zhongqi Pharmaceutical aims to enhance the company's position in the innovative biopharmaceutical sector, particularly focusing on GLP-1 target products, driven by increasing health awareness and medical spending in China [1][2] Group 1 - The joint venture will be funded with a total investment of 45 million RMB, with XinNuoWei contributing 15.75 million RMB (35% ownership) and Zhongqi Pharmaceutical contributing 29.25 million RMB (65% ownership) [1] - The joint venture will focus on the research, industrialization, and commercialization of innovative metabolic drugs, particularly targeting obesity and type 2 diabetes [1] - The joint venture will take over all GLP-1 related product pipelines from Shiyao Group, including preclinical, clinical, and market application stages, and will explore various methods to expand its product pipeline [2]

Core Viewpoint - The article highlights the increasing demand for investment in Hong Kong stocks, evidenced by record net inflows from mainland investors through the Stock Connect program, reaching 765.4 billion RMB as of July 25, 2024, surpassing the previous record of 744 billion RMB for the year [1]. Group 1: Investment Trends - The net inflow of funds into Hong Kong stocks has set a new historical high, indicating a strong and growing interest from investors [1]. - The proportion of Hong Kong stock assets in actively managed equity funds has been on the rise for six consecutive quarters, reaching 17.20% by the end of Q2 2025, compared to an average of 15.30% across all funds [4][6]. Group 2: Sector Allocation - The allocation to technology and internet sectors remains significant, with a 45.5% share in Q2 2025, although it has decreased from 49.9% in Q1 2025. The structure within this sector has seen some optimization, with a 3% decrease in the media sector and a 0.2% increase in the computer sector [6][7]. - The pharmaceutical and biotechnology sectors have emerged as the largest area of increased investment, with their share rising from 7.5% in Q1 to 13.7% in Q2 2025, marking a 6.2% increase [8]. - New consumption and high-dividend assets are forming a complementary allocation, with the light manufacturing sector and the financial sector seeing increases of 1.9% and 2.3%, respectively, in their market value proportions [9]. Group 3: Investment Opportunities for Retail Investors - The Hong Kong market features 163 A+H shares, representing only 6.15% of total listings, indicating a unique investment landscape compared to A-shares. The market offers distinct advantages in sectors like technology, internet, and innovative pharmaceuticals [10]. - Ordinary investors can access Hong Kong stocks through various means, including direct trading, ETFs, and mutual funds, with options available for different risk appetites and investment amounts [11][14].

Core Viewpoint - The pharmaceutical and biotechnology sector has shown strong performance recently, particularly in the medical services and medical devices sub-sectors, supported by government initiatives to empower innovation in drugs and medical devices [1] Group 1: Government Initiatives - The National Healthcare Security Administration (NHSA) has held two meetings to support innovative drugs and devices, focusing on establishing new medical service pricing projects and researching pricing mechanisms for newly launched drugs [1] - Following the approval of measures to optimize the lifecycle regulation supporting high-end medical device innovation, there is a clear trend of increasing support for innovative medical devices from top-level design, with more supportive policies expected in the future [1] Group 2: Market Dynamics - The NHSA emphasized that "winning bids in centralized procurement will no longer simply refer to the lowest price," indicating a specific implementation of "anti-involution" actions in the medical field, which is expected to lead to orderly competition and an overall improvement in profitability and valuation levels in the medical device sector [1] - The ChiNext Medical ETF (159377) tracks the ChiNext Medical Index (399275), which can fluctuate by up to 20% in a single day, focusing on innovative biopharmaceuticals and selecting securities from companies involved in biotechnology, drug development, and related services [1] - The index emphasizes allocation in sub-sectors such as biotechnology and new drug development, highlighting the market trends of innovative pharmaceutical companies [1]